Princeton, NJ-based Celator Pharmaceuticals has raised close to $40 million, enough to get its lead cancer drug--a reformulation of standard drugs infused in nano-sized delivery vehicles--through a pivotal late-stage study that is now enrolling patients with secondary cases of acute myeloid leukemia.
The Cambridge, MA-based developer, which is focused on new therapies for osteoporosis, says that F2 Biosciences III stepped up to lead the latest round of $43 million.
Now that the successful biopharma team of Roger Newton and Tim Mayleben has reunited to run an upstart--Esperion--with a promising mid-stage cholesterol drug in the pipeline, some well-known names in the venture crowd have decided to tag along and see if they just might have a big winner on their hands.
Driven to test another amyloid-beta mechanism in Alzheimer's, Acumen Pharmaceuticals has wrapped up the first closing of a planned $20 million Series A round from BVF Partners, NeuroVentures Fund, Praxis Technologies, Glynn Ventures and private backers.
The company plans to spend the capital on advancing a pipeline of vaccines, including a Phase II trial for a candidate called ProCervix for patients with high-risk cases of human papillomavirus (HPV) infection.
The London-based drug giant has partnered with veteran life sciences investors at Avalon Ventures to bankroll a crop of drug-hunting startups in San Diego, with GSK committing the bulk of the alliance's $495 million to fuel the new companies.
Ask any biotech exec in the business of drug and device development about the funding environment these days, and you'll most likely hear the word "tough" inside of three seconds. The...
The VC industry turned in bleak numbers for biotech deal-making in the first quarter of 2013, with one key measure of early-stage activity in the life science sector falling to its lowest level in almost 18 years.
The Cambridge, MA-based biotech company has proposed to raise up to $69 million in a public debut, with plans to spend proceeds from the deal on advancing clinical trials for its top candidates against cancer-related epigenetic enzymes.
The startup plans to use the money to fund clinical development of a pair of antibiotics against multi-drug resistant gram-negative bacteria, which have grabbed headlines as some of the most dangerous superbugs around.